Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Int J Cancer. 2014 Jun 13;136(2):452–461. doi: 10.1002/ijc.28994

Figure 5.

Figure 5

Antitumor efficacy of SN6j, sorafenib and capecitabine, and suppressive effect of SN6j on the tumor microvessels in the GEMs. (a, b) Suppression of Col 26 tumor (a) and 4T1 tumor (b) by SN6j and sorafenib. GEMs bearing established tumors (n = 10) were given SN6j (50 μg for Col 26 and 100 μg for 4T1) i.v. three times a week while sorafenib (20 mg/kg) was given orally three times a week. Administration of mAb/control IgG and sorafenib is indicated by arrows and arrow heads, respectively. (c) Growth of established tumor of Col 26 was suppressed by SN6j or capecitabine. SN6j or an isotype-matched control IgG (MOPC 195v) was given i.v. three times a week as indicated by arrows, while capecitabine (100 mg/kg) was given orally six times a week as indicated by arrow heads. Statistically significant (p < 0.05) antitumor activity is indicated by the star symbols. (d) Matrigel plug assay to measure effect of the i.v administered SN6j on the microvessel density of Col 26 tumor in the GEMs. SN6j effectively suppressed the microvessel density (p = 0.0247).